Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00481221
Other study ID # 5210906.EMC
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 2007
Est. completion date December 31, 2020

Study information

Verified date October 2019
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

β thalassemia is an autosomal recessive hemoglobinopathy and considered as the most widespread genetic mutation. According to the World Health Organization (WHO) between 1.5-7% of the world population are carriers for this disease, and every year 60,000-400,000 birth of new patients are reported. In Israel, the incidence of carriers for β thalassemia is around 20% among the Jewish from Kurdish origin and around 5-10% among the Arab population.

β thalassemia is a severe disease which requires many resources, both medical and financial. The disease is expressed by chronic hemolytic anemia which requires regular blood transfusions every 3 weeks. As a result of the blood transfusions and the iron absorption by the digestive tract, those patients suffer from severe hemosiderosis which is the main mortality cause in the disease, mainly in the second decade for life. Daily treatment with iron chelator is required. Moreover, despite the actual treatment, the quality of life of those patients is still low.

Therefore the implementation of a prevention program which includes finding an effective and inexpensive way for identifying the β thalassemia carriers is a humanitary and publicly important goal.

In β thalassemia carriers, laboratory tests will show hypochromic microcytic anemia. Those findings are similar in iron deficiency anemia, but the RBC number and the RDW are normal in thalassemia carriers.

Few researchers tried in the past to determine cutoff point for diagnosis of β thalassemia carriers by different formulas.

We used the algorithm SVM (support vector machine) to find a reliable formula that can separate patients with Iron deficiency anemia/ healthy from patients with β thalassemia minor (carriers). This formula can be inserted to any automatic blood counter and search for suspected carriers without deliberately intention and without any further blood test.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30000
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 17 Years to 50 Years
Eligibility Inclusion Criteria:

- Blood count and Hgb electrophoresis analysis received from pregnant women send for screening for thalassemia.

Exclusion Criteria:

- Age below 17 yrs and older than 50 yrs.

- Sever anemia with hgb level below 8 gr/dl.

Study Design


Intervention

Procedure:
Observation of results from laboratory tests
Laboratory data summary only

Locations

Country Name City State
Israel Pediatric Hematology Unit - HaEmek Medical Center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detection of ß Thalassemia Carriers by Red Cell Parameters Detection of ß Thalassemia Carriers by Red Cell Parameters Obtained From the Automatic blood count counter using mathematics formula One year
See also
  Status Clinical Trial Phase
Completed NCT01483768 - Study of Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Recruiting NCT02242188 - Supplementing Iron and Development in Breastfed Infants (SIDBI Study) Phase 4
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01991626 - Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods N/A
Completed NCT01687062 - Iron Absorption From Tef-injera in Women of Reproductive Age N/A
Completed NCT01573013 - Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children N/A
Completed NCT01191463 - The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals and Its Effect on Iron Status of Rural Indian Children (6-10 Years) N/A
Completed NCT01443832 - Iron Absorption From Iron-fortified Fonio Porridge: a Stable Isotope Study Phase 0
Completed NCT01061307 - An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Phase 0
Not yet recruiting NCT00515918 - The Effect of Early Iron Deficiency on Developmental Brain and Behavior in Infants N/A
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Recruiting NCT05992116 - Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
Completed NCT05262634 - Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester
Completed NCT06080555 - Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia Phase 1
Completed NCT04602247 - Evaluation of Iron Bioavailability From Iron Chlorophyllin N/A
Completed NCT02996786 - Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners N/A
Completed NCT02175888 - The Optimization of Bioavailability From Iron Supplements: Study 1 N/A